Craft

Advanced
Genmab

Genmab

Stock Price

$23.1

2024-10-29

Market Capitalization

$14.7 B

2024-10-29

Revenue

$3.7 B

FY, 2025

Genmab Summary

Company Summary

Overview
Genmab is a biotechnology company that develops and commercializes antibody therapeutics to treat cancer. It offers bispecific T-cell engagers, antibody-drug conjugates, immune checkpoint modulators, antibodies, and other products.
Type
Public
Status
Active
Founded
1999
HQ
Copenhagen, DK | view all locations
Website
http://genmab.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Jan G. J. van de Winkel

    Jan G. J. van de Winkel, President & Chief Executive Officer

    • Anders Gersel Pedersen

      Anders Gersel Pedersen, Board Member

      • Marisol Peron

        Marisol Peron, Senior Vice President, Global Communications & Investor Relations

      • Yasir Nagarwala

        Yasir Nagarwala, Vice President, Global Medical Affairs

      Operating MetricsView all

      Trademarks

      285

      FY, 2018

      Trademarks (US)

      12

      FY, 2018

      Patents and Patent Applications

      1.1K

      FY, 2018

      LocationsView all

      4 locations detected

      • Copenhagen HQ

        Denmark

        Carl Jacobsens Vej 30

      • Plainsboro, NJ

        United States

        777 Scudders Mill Rd

      • Tokyo, Tokyo

        Japan

        35F, Midtown Tower, 9-7-1 Akasaka

      • Utrecht, UT

        Netherlands

        Uppsalalaan 15, P.O. Box 85199

      Genmab Financials

      Summary Financials

      Revenue (Q1, 2026)
      $896.0M
      Gross profit (Q1, 2026)
      $860.0M
      Net income (Q1, 2026)
      $53.0M
      Cash (Q1, 2026)
      $1.5B
      EBIT (Q1, 2026)
      $180.0M
      Enterprise value
      $18.5B

      Competitors and Similar Companies

      Compare competitors

      Footer menu

      Product

      Solutions

      Resources

      Company

      © Craft.co 2026
      Share price data provided by IEX